Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.47 |
| ▸ | BRAF | P15056 | 8/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.45 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227773 | 0.82 | KIT (0.65) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL29614753 | 0.82 | KIT (0.65) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL27088026 | 0.80 | NR1H2 (0.64) | KITBRAFSRCEGFRCDK1 | |
| SCHEMBL30486126 | 0.79 | KIT (0.43) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL30486106 | 0.79 | KIT (0.44) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL29958951 | 0.78 | DDR1 (0.49) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL30900112 | 0.78 | CYP2C9 (0.52) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL16380144 | 0.76 | RET (0.63) | KITBRAFSRCEGFRABL1 | |
| SCHEMBL30486109 | 0.75 | KIT (0.49) | KITBRAFSRCABL1BCR | |
| SCHEMBL27088034 | 0.75 | KCNJ1 (0.43) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KIT 4277/4885BRAF 1615/4885SRC 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.